How Different Beta-2 Receptor Genotypes Affect an Asthmatic's Response to Regular Salmeterol Treatment - Full Text View

Sponsored by:	Brigham and Women's Hospital
Information provided by:	Brigham and Women's Hospital
ClinicalTrials.gov Identifier:	NCT00595361

Purpose

The purpose of the study is to find out how well a long-acting beta agonist like salmeterol works in people with different forms of the same gene. Our hypothesis is that asthmatics with the Arg/Arg genotype will have loss of bronchoprotection against exercise-induced asthma with regular salmeterol treatment, as compared to asthmatics with the Gly/Gly genotype.

Condition	Intervention
Asthma	Drug: salmeterol

MedlinePlus related topics: Asthma Exercise and Physical Fitness

Drug Information available for: Salmeterol Salmeterol xinafoate Isoetharine Isoetharine hydrochloride Isoetharine mesylate

U.S. FDA Resources

Study Type:

Interventional

Study Design:

Treatment, Double Blind (Subject, Investigator), Uncontrolled, Parallel Assignment, Safety/Efficacy Study

Official Title:

The Effect of Beta-2 Adrenergic Polymorphisms on the Bronchoprotective Effects of Regular Salmeterol Treatment in Asthma

Further study details as provided by Brigham and Women's Hospital:

Primary Outcome Measures:

comparison of the maximum percent fall in FEV1 after exercise challenge at the end of the 2-week treatment period between Arg/Arg and Gly/Gly patients [ Time Frame: 2 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

comparison of the maximum percent fall in FEV1 from pre-salmeterol baseline to the end of the 2-week treatment period between Arg/Arg and Gly/Gly subjects [ Time Frame: 2 weeks ] [ Designated as safety issue: Yes ]
comparison of the maximum percent fall in FEV1 after 1st dose of salmeterol to the end of the 2-week treatment period between Arg/Arg and Gly/Gly subjects [ Time Frame: 2 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment:

30

Study Start Date:

January 2008

Estimated Study Completion Date:

June 2009

Estimated Primary Completion Date:

February 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Arg/Arg: Active Comparator Arg/Arg subjects on 2 week salmeterol treatment	Drug: salmeterol salmeterol 50 micrograms twice daily for 2 weeks
Gly/Gly: Active Comparator Gly/Gly subjects on 2 week salmeterol treatment	Drug: salmeterol salmeterol 50 micrograms twice daily for 2 weeks

Detailed Description:

In many patients with asthma, exercise-induced bronchoconstriction is a common and oftentimes limiting characteristic. Inhaled β2-adrenoreceptor agonists like albuterol are the most effective treatments available for the relief of acute asthma symptoms. However, there is evidence that regular use may lead to adverse effects in some patients. Previous studies have shown that polymorphisms of the β2-adrenergic receptor can influence airway responses to regular inhaled beta-agonist treatment.

Pharmacogenetics is the study of how genetic differences influence the variability in patients' responses to therapy, both therapeutic and adverse. Genetic susceptibility and environmental factors both play major roles in the etiology of asthma. The strong familial clustering of asthma has lead to a surge of research into the genetic predisposition of asthma. The aim of the present study is to utilize a double-blinded prospective cohort study to investigate whether genotype-specific effects occur when assessing the duration of protection conferred against exercise-induced bronchoconstriction by regular salmeterol treatment.

Eligibility

Ages Eligible for Study:

18 Years to 50 Years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

Yes

Criteria

Inclusion Criteria:

Both male and female
18 to 50 years of age
Resting FEV1 ≥ 65% of predicted normal
Exercise-induced bronchoconstriction defined as a decrease in FEV1 of ≥ 20% following a standardized exercise challenge when compared to pre-exercise baseline FEV1 value measured 5 minutes before exercise
Must be Arg/Arg or Gly/Gly genotype

Exclusion Criteria:

Long-acting beta agonist use within 12 weeks of the first exercise challenge
Smoking within past 12 months
Greater than 10-pack years smoking history
Unresolved signs and/or symptoms of an upper respiratory tract infection within 4 weeks of first exercise challenge
Asthma exacerbation within 4 weeks of first exercise challenge requiring change in type, dose or frequency of medications and/or an unscheduled visit to an health care provider, including emergency room or hospital
Subject has exercised or performed strenuous activity within 72 hours of the first exercise challenge
Subject has been exposed to cold air sufficient to provoke symptoms of bronchospasm within 2 hours of exercise challenge
In addition to asthma, the subject has an active, acute or chronic pulmonary disorder documented by history, physical examination, or chest x-ray
Subject has evidence of ischemic, valvular, hypertrophic, familial or other forms of heart disease that would put the subject at risk during exercise testing or that would interfere with the ability to achieve protocol-specified heart rates during exercise testing
Subject has used systemic corticosteroids within 1 month of first exercise challenge

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00595361

Contacts

Contact: Perdita Permaul, M.D.

617-732-8201

PPermaul@partners.org

Locations

United States, Massachusetts
Asthma Research Center, Brigham and Women's Hospital	Recruiting
Boston, Massachusetts, United States, 02115
Sub-Investigator: Perdita Permaul, M.D.

Sponsors and Collaborators

Brigham and Women's Hospital

Investigators

Principal Investigator:

Elliot Israel, M.D.

Asthma Research Center, Brigham and Women's Hospital

More Information

Publications of Results:

Israel E, Drazen JM, Liggett SB, Boushey HA, Cherniack RM, Chinchilli VM, Cooper DM, Fahy JV, Fish JE, Ford JG, Kraft M, Kunselman S, Lazarus SC, Lemanske RF, Martin RJ, McLean DE, Peters SP, Silverman EK, Sorkness CA, Szefler SJ, Weiss ST, Yandava CN. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med. 2000 Jul;162(1):75-80.

Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, Deykin A, Fagan JK, Fahy JV, Fish J, Kraft M, Kunselman SJ, Lazarus SC, Lemanske RF Jr, Liggett SB, Martin RJ, Mitra N, Peters SP, Silverman E, Sorkness CA, Szefler SJ, Wechsler ME, Weiss ST, Drazen JM; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet. 2004 Oct 23;364(9444):1505-12.

Wechsler ME, Lehman E, Lazarus SC, Lemanske RF Jr, Boushey HA, Deykin A, Fahy JV, Sorkness CA, Chinchilli VM, Craig TJ, DiMango E, Kraft M, Leone F, Martin RJ, Peters SP, Szefler SJ, Liu W, Israel E; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med. 2006 Mar 1;173(5):519-26. Epub 2005 Dec 1.

Ramage L, Lipworth BJ, Ingram CG, Cree IA, Dhillon DP. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med. 1994 May;88(5):363-8.

Yates DH, Worsdell M, Barnes PJ. Effect of regular salmeterol treatment on albuterol-induced bronchoprotection in mild asthma. Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):988-91.

Nelson JA, Strauss L, Skowronski M, Ciufo R, Novak R, McFadden ER Jr. Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med. 1998 Jul 16;339(3):141-6.

Palmer CN, Lipworth BJ, Lee S, Ismail T, Macgregor DF, Mukhopadhyay S. Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax. 2006 Nov;61(11):940-4. Epub 2006 Jun 13.

Israel E. Genetics and the variability of treatment response in asthma. J Allergy Clin Immunol. 2005 Apr;115(4 Suppl):S532-8. Review.

Responsible Party:

Asthma Research Center/Brigham and Women's Hospital ( Elliot Israel, M.D. )

Study ID Numbers:

2007-P-002199

First Received:

January 7, 2008

Last Updated:

March 14, 2008

ClinicalTrials.gov Identifier:

NCT00595361

Health Authority:

United States: Institutional Review Board

Keywords provided by Brigham and Women's Hospital:

asthma
exercise induced asthma
exercise induced bronchoconstriction
long acting beta agonist
salmeterol

exercise challenge
bronchoprotection
beta 2 adrenergic receptor polymorphisms
pharmacogenetics

Study placed in the following topic categories:

Asthma, Exercise-Induced
Hypersensitivity
Lung Diseases, Obstructive
Salmeterol
Respiratory Tract Diseases

Lung Diseases
Hypersensitivity, Immediate
Asthma
Respiratory Hypersensitivity

Additional relevant MeSH terms:

Respiratory System Agents
Neurotransmitter Agents
Bronchial Diseases
Immune System Diseases
Adrenergic beta-Agonists
Adrenergic Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs

Anti-Asthmatic Agents
Adrenergic Agonists
Pharmacologic Actions
Autonomic Agents
Therapeutic Uses
Peripheral Nervous System Agents
Bronchodilator Agents

ClinicalTrials.gov processed this record on January 07, 2009